

2nd Edelris Symposium on Affinity Selection-Mass Spectrometry in Drug Discovery

Programme

Wednesday 08/06/2022

16:00 Opening & Introduction

Dr Jean-Yves ORTHOLAND
(EDELRIIS, Lyon, France)

Session Session 1

16:05 PL01 - Using Affinity-selection MS to Find Compounds that Disrupt RNA Structure and X-Chromosome Inactivation via Xist

Dr Elliott B. NICKBARG
(MERCK & CO., INC., Boston, United States)

16:40 PL02 - Challenges and Opportunities in the Application of Affinity Selection Mass Spectrometry in Early Drug Discovery

Dr Manuel Francisco MOLINA-MARTIN
(LILLY LABORATORIES, Madrid, Spain)

17:15 PL03 - Utilizing Mass Spectrometry to Discover RNA-binding Small Molecules

Dr Scott RUSIN
(ARRAKIS THERAPEUTICS, Waltham, MA, United States)

17:50 Break

18:00 Roundtable discussion & Closing remarks

Dr Elliott B. NICKBARG (MERCK & CO., INC., Boston, United States)
Dr Scott RUSIN (ARRAKIS THERAPEUTICS, Waltham, MA, United States)
Dr Manuel Francisco MOLINA-MARTIN (LILLY LABORATORIES, Madrid, Spain)
Dr Didier ROCHE (EDELRIIS, Lyon, France)

2nd Edelris Symposium on Affinity Selection-Mass Spectrometry in Drug Discovery

Programme

Thursday 09/06/2022

16:00 Opening remarks Day 2

Dr Allen ANNIS
(AILERON THERAPEUTICS, Cambridge, United States)

Session Session 2

16:05 PL04 - Affinity Selection-Mass Spectrometry for Oligonucleotides, Proteins, Cells, and Animals

Prof. Bradley Lether PENTELUTE
(MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA, United States)

16:40 PL05 - Affinity Selection Mass Spectrometry (ASMS) for Experimental Target Tractability Assessment (eTA)

Dr Lauren KUSTIGIAN
(GSK, Collegeville, PA, United States)

17:15 PL06 - Difficulties and Solutions Along the ASMS Data Analysis Pathway

Dr Mark SPEARS
(VIRSCIDIAN, Cary, NC, United States)

17:50 Break

18:00 Roundtable discussion & Closing remarks

Prof. Bradley Lether PENTELUTE (MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, MA, United States)
Dr Lauren KUSTIGIAN (GSK, Collegeville, PA, United States)
Dr Mark SPEARS (VIRSCIDIAN, Cary, NC, United States)
Dr Allen ANNIS (AILERON THERAPEUTICS, Cambridge, United States)